Precipio, Inc. (PRPO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US74019L6020
Precipio, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 24.05 m USD |
| Gross profit | 10.71 m USD |
| Operating income | -1.20 m USD |
| EBIT | -363,000.00 USD |
| Net income | -363,000.00 USD |
| Diluted EPS – continuing operations | -0.23 USD |
Full history since 1999, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Precipio, Inc.
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
More stocks
- Poled (487580.KQ)
- Nyquest Technology Co Ltd (6494.TWO)
- HYPERION DEFI, INC. (HYPD)
- Carbon-Based Technology Inc. (7719.TWO)
- Protia Inc. (303360.KQ)
- VirnetX Holding Corp (VHC)
- XTI Aerospace, Inc. (XTIA)
- Cytogen Inc (217330.KQ)
- Momentus Inc. (MNTS)
- Eltek Ltd (ELTK)
- Galaxy Gaming, Inc. (GLXZ)
- Heritage Global Inc. (HGBL)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.